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To the Editor:
We read with interest the recent article in Nature Medicine describing the influence of
variation in CCL3L1 copy number and CCR5 genotype on immune recovery during highly
active antiretroviral therapy (HAART) in HIV-1 infected individuals1. The chemotactic
cytokine CCL3L1 (encoding the MIP-1αP protein) is a potent ligand for the HIV-1
coreceptor CCR5, which is essential for viral entry into human host cells2. The recent study
is part of a series that began in 2005 with a paper reporting effects of CCL3L1 copy number
variation on HIV-1 acquisiton, viral load, and disease progression3, followed by several
publications investigating clinically correlated phenotypes in a largely overlapping set of
HIV+ individuals1,4,5.
While these studies appear to generate considerable independent support for a role of
CCL3L1 in viral control, many of the traits considered are at least partially correlated and
the studies include largely overlapping samples and presumably CCL3L1 assay data. For
these reasons we sought to re-evaluate a core set of associations related to the effect of
CCL3L1 on viral control in a large group of HIV-infected patients with known date of
seroconversion enrolled in one of the nine cohorts of the Euro-CHAVI Consortium6
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On behalf of the Center for HIV/AIDS Vaccine Immunology (CHAVI) and the Euro-CHAVI consortia (A.T., D.B.G.), the
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(http://www.chavi.org, n = 1,042), in an African-American cohort from the Tri-Service
AIDS Clinical Consortium (TACC) (http://www.idcrp.org/tacc2.html, n = 277) or in the
Multicenter AIDS Cohort Study (MACS) (http://www.statepi.jhsph.edu/macs/macs.html) (n
= 451 HIV+, n = 195 high-risk seronegative). We assayed for CCL3L1 copy number using
the method described by Gonzalez et al. 3 (Supplementary Methods online). A total of 1,855
subjects were successfully genotyped. Distributions of CCL3L1 copy numbers in patients of
European or African ancestry were similar to those reported elsewhere, with a median copy
number of 2 or 4 in individuals of primarily European (range 0-9) or African (range 1-11)
descent, respectively (Fig. 1a,b)1,3,4,7.
We then tested for association of CCL3L1 copy number with HIV viral load at set point by
linear regression after stratifying according to ethnicity and correcting for known covariates
(gender, age at seroconversion, and ancestry as determined by a principal components
method described previously8), and found no evidence of association (European:, P = 0.14;
African: P = 0.27) (Fig. 1c,d). Dividing the sample into the previously described “high risk”
(CCL3L1low) and “low risk” (CCL3L1high) genotype groups (where high risk vs. low risk is
defined as having copy number below vs. equal to or above the population median,
respectively)3, we again found no evidence of association, either within each population
(European: P = 0.10; African: P = 0.41) or in the combined sample (P = 0.35) (Table 1).
Furthermore, a model including known functional polymorphisms in the CCR5 receptor
(CCR5Δ32, CCR5*HHE) in a subset of n=820 individuals of European descent for which
CCR5 effects had been tested previously (Fellay et al., unpublished data), showed that while
the CCR5 polymorphisms were strongly associated with viral load (CCR5Δ32: β = -0.29 +/-
0.08 log RNA copies, P = 0.001; CCR5*HHE: β = 0.14 +/- 0.05 log RNA copies, P =
0.005), there remained no appreciable effect of CCL3L1 copy number (copy number: P =
0.24; genotype risk group: P = 0.12).
We next tested whether CCL3L1 variation influences disease progression. We used both a
quantitative measure of progression introduced by Fellay et al.6 (consisting of measured or
estimated time to CD4+ cell count <350/mm3 or initiation of antiretroviral therapy;
Supplemental Methods online) and a simple case/control comparison of progressors vs. non-
progressors (defined as progression to CD4+ cell count <350/mm3 or antiretroviral therapy
within 10 years since seroconversion vs. no progression within 10 years). Finally, we tested
for an effect of CCL3L1low vs. CCL3L1high group on these measures as well as progression
to AIDS 1987, AIDS 1993, or AIDS-related death using a Cox proportional hazards model.
Neither CCL3L1 copy number nor CCL3L1low vs. CCL3L1high genotype group assignment
was associated with disease progression under any of these models (P > 0.1 for all tests)
(Table 1).
We then tested whether CCL3L1 copy number was associated with risk of HIV infection by
comparing the copy number distributions in HIV-infected patients (HIV+) compared with
individuals who were judged to be unusually exposed to HIV but remain uninfected (called
high-risk seronegative, or HSRN). Using samples from the MACS cohort we compared 451
HIV+ to 195 HRSN individuals. This comparison was well powered to detect effects of
CCL3L1 copy number on risk of infection through mucosal exposure (the principal model of
transmission in this cohort). No association was found between infection status and either
copy number (P = 0.53) or genotype risk group (P = 0.18) (Table 1). In the same sample,
CCR5Δ32 homozygosity was strongly associated with reduced risk of infection (CCR5Δ32/
CCR5Δ32 genotype frequency: 4.9% in exposed uninfected vs. 0% in infected individuals, P
= 3.5 × 10-6). Of note is the enrichment of CCR5Δ32 homozygotes in the HRSN sample
(4.9% vs. an estimated 1% in unselected individuals of European descent)9, demonstrating
that the effective exposure in the HRSN cohort was very high and therefore that this cohort
should provide sufficient power to detect additional genetic risk factors of reasonable effect
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size. Notably, we also found no effect of CCL3L1 copy number on infection risk after
stratifying according to CCR5Δ32 genotype.
We investigated whether CCL3L1 copy number influences CCL3L1 mRNA expression in
CD4+ T lymphocytes from 122 HIV+ patients who had not yet initiated antiretroviral
therapy, using the Illumina WG-6 v3 expression array (Supplementary Methods online), and
found a strong and linear increase of CCL3L1 mRNA levels with copy number (r2 = 0.23, P
= 3.0 × 10-8, Fig. 1e). In the same samples, however, CCL3L1 mRNA expression itself
shows no correlation with HIV set point (r2 = 0.003, P = 0.51, Fig. 1f).
These observations raise the question of why earlier studies reported positive associations
which cannot be replicated here. As a possible explanation we note that measurement of
CCL3L1 copy number variation appears highly susceptible to systematic biases related to
the preparation and quality of DNA samples. We observed that batch differences in input
DNA amounts between cases and controls can lead to biased copy number estimates by the
real-time PCR method used here, and in fact found an apparently significant association in
the direction opposite to that previously reported (with higher copy number among HIV+
cases compared with controls) before diluting DNA samples into an appropriate range
(Supplementary Methods online). Additionally, we compared the results of different assays
(the real-time PCR based assay used here and in the previous reports, and a recently
published method based on the paralogue ratio test (PRT)10,11) and found that although the
results were generally very highly correlated, for one comparison the association statistics
from the two assays diverged markedly. Specifically, in a comparison of a small number of
HIV+ and HIV- samples from Malawi, copy number estimated by the PRT method showed a
strong association with infection status, whereas the real-time PCR-based estimates showed
no association; this discrepancy appears to be explained by systematic differences in DNA
degradation between case and control samples, in which degradation or shearing of DNA
leads to systematic overestimation of copy number by the PRT method specifically
(Supplementary Methods online). Among HIV+ individuals, we did not observe either assay
method recording a signal of association for any HIV related quantitative trait; these tests
are both more statistically powerful than the case/control comparisons and far less sensitive
to any “batch effects” on the copy number estimation. Although both of the assays described
here are liable to different types of systematic biases, we emphasize that differences between
cohorts in the distribution of DNA concentrations are presumed to be far more likely, and
perhaps expected, compared with differences in DNA storage or degradation, and thus the
real-time PCR method will often be expected to produce a false positive association unless
input DNA amounts are carefully considered. We therefore suggest that some of the
previously reported associations may reflect differences in DNA quality or concentration
which systematically increase or decrease the inferred number of copies of CCL3L1 in cases
vs. control samples.
In summary, we find the absence of any significant effect of CCL3L1 copy number variation
on HIV-1 infection, viral load, or disease progression. We do, however, show a highly
significant association of copy number variation with CCL3L1 mRNA levels, demonstrating
that the assays are sufficiently accurate to detect the intermediate biological effects of copy
number variation. While there is some evidence that reduced expression of the CCR5
receptor may aid in viral control and delay progression to AIDS, there is less reason to
believe that CCR5 inhibition is protective from infection without complete CCR5 blockade.
Others have demonstrated that CCL3L1/MIP-1αP is expressed at relatively low levels
compared with other CCR5 ligands, with measured serum concentrations well below its
estimated EC50 based on ex vivo assays7,12. Indeed, concentration increases to orders of
magnitude higher than those reported in both healthy and HIV-infected individuals would
appear to be required to approach half-maximal occupancy by CCL3L1, whereas a reduction
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in receptor concentration would effectively multiply the affinity of all CCR5 ligands,
including the much more abundant CCL5 (RANTES) and others in addition to MIP-1αP7.
We should note that these arguments do not apply to the postulated effects of CCL3L1 that
operate independently of direct CCR5 blockade, for example through effects on the
expression of innate defense pathways. Such an explanation, however, might also be
expected to drive correlations between CCL3L1 expression and viral control in infected
individuals which were not observed (Fig. 1d). We point out that a gold standard for copy
number determination in this region is yet lacking, and that the current techniques are likely
to be influenced by other sources of error beyond the systematic ones describered here.
Despite progress in cataloging sequence and structural variation in the CCL3L1 region13,
accurate assessment of the contribution of genetic variation in such a complex region will
require the development of more accurate assay methods which provide information not
only about gene copy number but also gene content. Finally, we emphasize that these results
do not cast any doubt on efforts to develop CCR5 antagonists (i.e. MIP-1αP analogs) as
therapeutics for HIV prevention and treatment, but merely argue that natural variation in
CCL3L1 gene dose does not appear to have any important effects on the control of HIV-1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(a and b) Distribution of CCL3L1 copy number in HIV-infected individuals of recent (a)
European or (b) African ancestry. Median CCL3L1 copy number was 2 in patients of recent
European descent and 4 in patients of recent African descent. (c and d) Relationship
between HIV viral load at setpoint and CCL3L1 copy number among patients of recent
European (c) or African (d) ancestry. Linear regression of HIV viral load at setpoint on
CCL3L1 copy number showed no significant effect of CCL3L1 dose (European: r2 = 0.0006,
P = 0.14; African: r2 = 0.0022, P = 0.27). (e and f) Relationship among CCL3L1 copy
number, CCL3L1 mRNA expression, and viral load at set point. Specific expression of
CCL3L1 mRNA in CD4+ T cells was determined using the Illumina WG-6 v3 expression
array. CCL3L1 expression in CD4+ T lymphocytes showed a strong correlation with copy
number, but was not associated with viremia.
Urban et al. Page 6
Nat Med. Author manuscript; available in PMC 2010 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Urban et al. Page 7
Ta
bl
e 
1
R
es
ul
ts
 o
f s
ta
tis
tic
al
 te
st
s f
or
 a
ss
oc
ia
tio
n 
of
 C
C
L3
L1
 c
op
y 
nu
m
be
r o
r g
en
ot
yp
e 
ris
k 
gr
ou
p 
(G
R
G
) s
ta
tu
s w
ith
 H
IV
 in
fe
ct
io
n 
ris
k 
or
 H
IV
-r
el
at
ed
 o
ut
co
m
es
.
C
on
tin
uo
us
 T
ra
its
n
be
ta
r2
p-
va
lu
e
Se
t p
oi
nt
 v
s. 
co
py
 n
um
be
r (
EU
R
)
11
38
-.0
34
2
0.
00
06
0.
14
Se
t p
oi
nt
 v
s. 
co
py
 n
um
be
r (
A
FR
)
36
6
.0
24
4
0.
00
22
0.
27
Se
t p
oi
nt
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (E
U
R
)
11
38
-.1
02
2
0.
00
19
0.
10
Se
t p
oi
nt
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (A
FR
)
36
6
.0
74
1
0.
00
21
0.
41
Se
t p
oi
nt
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (c
om
bi
ne
d)
15
04
-.0
39
5
0.
00
06
0.
42
Ti
m
e 
to
 p
ro
gr
es
si
on
 v
s. 
co
py
 n
um
be
r (
EU
R
)
68
2
6.
64
0.
00
02
0.
90
Ti
m
e 
to
 p
ro
gr
es
si
on
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (E
U
R
)
68
2
62
.5
0.
00
01
0.
65
B
in
ar
y 
Tr
ai
ts
n 
(p
ro
gr
es
so
r)
n 
(n
on
pr
og
re
ss
or
)
O
dd
s R
at
io
p-
va
lu
e
Pr
og
re
ss
or
/N
on
pr
og
re
ss
or
 v
s. 
co
py
 n
um
be
r (
EU
R
)
61
1
71
1.
14
0.
33
Pr
og
re
ss
or
/N
on
pr
og
re
ss
or
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (E
U
R
)
61
1
71
1.
25
0.
46
Su
rv
iv
al
 A
na
ly
si
s
n
H
az
ar
d 
ra
tio
95
%
 C
I
p-
va
lu
e
Ti
m
e 
to
 p
ro
gr
es
si
on
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
 (E
U
R
)
74
4
0.
95
 +
/- 
0.
09
0.
78
 –
 1
.1
5
0.
59
Te
st
s f
or
 A
ss
oc
ia
tio
n 
w
ith
 In
fe
ct
io
n 
St
at
us
n 
(H
IV
+ )
n 
(H
R
SN
)
O
dd
s R
at
io
 (9
5%
 C
I)
p-
va
lu
e
H
IV
 in
fe
ct
io
n 
st
at
us
 v
s. 
co
py
 n
um
be
r
45
1
19
5
0.
86
 –
 1
.0
8
0.
53
H
IV
 in
fe
ct
io
n 
st
at
us
 v
s. 
C
C
L3
L1
hi
gh
/C
C
L3
L1
lo
w
45
1
19
5
0.
52
 –
 1
.1
3
0.
18
EU
R
, i
nd
iv
id
ua
ls
 o
f r
ec
en
t E
ur
op
ea
n 
an
ce
st
ry
; A
FR
, i
nd
iv
id
ua
ls
 o
f r
ec
en
t A
fr
ic
an
 a
nc
es
try
 (A
fr
ic
an
 E
ur
op
ea
ns
 a
nd
 A
fr
ic
an
 A
m
er
ic
an
s)
. B
et
a,
 o
dd
s r
at
io
s, 
ha
za
rd
 ra
tio
s a
nd
 p
-v
al
ue
s a
re
 re
po
rte
d 
fo
r t
he
C
C
L3
L1
 c
op
y 
nu
m
be
r o
r G
R
G
 te
rm
 a
fte
r a
dj
us
tin
g 
fo
r g
en
de
r, 
ag
e 
at
 se
ro
co
nv
er
si
on
, a
nd
 p
op
ul
at
io
n 
st
ru
ct
ur
e.
 R
2  
va
lu
es
 re
pr
es
en
t t
he
 fr
ac
tio
n 
of
 v
ar
ia
tio
n 
ex
pl
ai
ne
d 
by
 th
e 
C
C
L3
L1
 c
op
y 
nu
m
be
r o
r G
R
G
te
rm
 b
ef
or
e 
co
rr
ec
tio
n 
fo
r o
th
er
 c
ov
ar
ia
te
s.
Nat Med. Author manuscript; available in PMC 2010 February 15.
